CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

04 Apr 2024 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 Mar 2024 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

05 Mar 2024 13:30:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

15 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

07 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

12 Dec 2023 13:02:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

06 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

18 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

27 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

29 Aug 2023 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

13 Jul 2023 20:15:49 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Proposed Public Offering of Common Stock

13 Jul 2023 13:03:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

13 Jul 2023 13:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

06 Jul 2023 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

31 May 2023 13:00:25 By Nasdaq GlobeNewswire